Here's What to Expect From Brown-Forman's Next Earnings Report
Ahead of the event, analysts expect BF.B to report a profit of $0.37 per share, down 9.8% from $0.41 per share reported in the year-ago quarter. It has exceeded analysts' earnings estimates in two of the past four quarters while missing on two occasions.
More News from Barchart
Warren Buffett Warns Inflation Turns Business Into 'The Upside-Down World of Alice in Wonderland' But Weeds Out 'Bad Businesses'
Why GOOGL Stock May Be the Market's Next Big Winner
Alphabet Posts Lower Free Cash Flow and FCF Margins - Is GOOGL Stock Overvalued?
Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else.
For the current year, analysts expect BF.B to report EPS of $1.67, down 9.2% from $1.84 in fiscal 2024. However, analysts expect its earnings to surge 3% year-over-year to $1.72 per share in fiscal 2026.
Over the past year, BF.B shares declined 31.3%, underperforming the S&P 500 Index's ($SPX) 18.3% gains and the Consumer Staples Select Sector SPDR Fund's (XLP) 4.9% returns over the same time frame.
Shares of Brown-Forman fell 17.9% following the release of its Q4 2025 earnings on Jun. 5. The company posted revenue of $894 million in the period, which fell short of Street forecasts. Moreover, its adjusted EPS for the quarter amounted to $0.31, which fell short of consensus estimates by 13.9%.
The consensus opinion on BF.B stock is skeptical, with an overall 'Hold' rating. Out of the 17 analysts covering the stock, opinions include three 'Strong Buys,' 11 'Holds,' one 'Moderate Sell,' and two 'Strong Sells.' The mean price target of $32.49 indicates a 4.9% upside potential from current price levels.
On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Why Casella Waste Systems Stock Flopped on Friday
Key Points The company's bottom-line miss in its second quarter was striking. That was compounded by a guidance reduction for full-year profitability. 10 stocks we like better than Casella Waste Systems › Solid waste and recycling management company Casella Waste Systems (NASDAQ: CWST) was surely eager to start its weekend. On Friday, the company published quarterly results that were a dud with investors, who sent its share price down by more than 5%. That was more deeply in the red than the S&P 500 index's 1.6% dive. One big whiff Much of this was because of a fairly wide bottom-line miss in Casella's second quarter, the results of which were published after market close Thursday. In the quarter, Casella booked revenue of over $465 million. So far, so good, as this was more than 23% higher than in the same quarter of 2024. Further down the profit and loss statement, however, the company revealed that its generally accepted accounting principles (GAAP) net income fell to $5.2 million ($0.08 per share) from the year-ago profit of slightly over $7 million. That drop was discouraging enough, but it was exacerbated by the fact that analysts were expecting far better from the company. On average, they were modeling $0.33 per share for bottom-line profitability, although they underestimated revenue with a collective $454 million projection. Acquisitions played a role in Casella's top-line growth, as the company completed six buyouts across the first half of this year. Management also said higher landfill volumes were a catalyst. Notable guidance revisions Outside of the bottom-line miss, Casella's change in guidance was dismaying for investors. Although it raised its outlook for full-year 2025 revenue -- $1.82 billion to $1.84 billion from just under $1.78 billion to a bit over $1.8 billion -- it cut that for profitability. The company now believes its GAAP net income will land at $8 million to $18 million; the previous guidance called for $10 million to $25 million. Should you buy stock in Casella Waste Systems right now? Before you buy stock in Casella Waste Systems, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Casella Waste Systems wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $625,254!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,090,257!* Now, it's worth noting Stock Advisor's total average return is 1,036% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Casella Waste Systems Stock Flopped on Friday was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21 minutes ago
- Yahoo
Why Novo Nordisk Stock Bumped Higher on Friday
Key Points The Federal government might boost its support of weight-loss drugs soon. According to a media report, it's contemplating a five-year, experimental program that would subsidize their costs for qualifying patients. 10 stocks we like better than Novo Nordisk › Unexpected news of a potential support program from the federal government boosted the share prices of weight-loss drug developers on Friday. The poster boy for that still rather small group, Wegovy/Ozempic maker Novo Nordisk (NYSE: NVO), understandably saw a stock price lift that day. It rose by more than 2%, contrasting well with the 1.6% slide of the S&P 500 index. Federal help for obesity drugs? That news came from The Washington Post, which published an article stating that the Trump administration is planning an experimental program that would cover the costs of such medications. Citing documents from the Centers for Medicare and Medicaid Services (CMS) it had obtained, the newspaper said the plan would be implemented by state Medicaid administrations. It would also be utilized by Medicare Part D insurance plans. These entities would be allowed to cover weight-loss drugs for qualifying patients. At the moment, Medicare generally covers such treatments for patients who suffer from type 2 diabetes. Both Novo Nordisk's Wegovy and rival Eli Lilly's Zepbound are essentially versions of predecessor diabetes drugs. Some private insurance plans cover obesity medications. The Post wrote that the experimental program will last for five years. Massive potential impact Novo Nordisk hasn't yet commented on the article, but we can be sure the company is excited about the prospect. Combined, Medicare and Medicaid are immense programs. Even if only a few states are willing to cover weight-loss treatments through them, the company could experience a surge in sales. For the stock's investors, this is a potentially very impactful development well worth monitoring. Should you buy stock in Novo Nordisk right now? Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $625,254!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,090,257!* Now, it's worth noting Stock Advisor's total average return is 1,036% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Why Novo Nordisk Stock Bumped Higher on Friday was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21 minutes ago
- Yahoo
Alpha IVF Group Berhad Full Year 2025 Earnings: Misses Expectations
Alpha IVF Group Berhad (KLSE:ALPHA) Full Year 2025 Results Key Financial Results Revenue: RM176.8m (up 5.5% from FY 2024). Net income: RM57.5m (up 8.5% from FY 2024). Profit margin: 33% (in line with FY 2024). EPS: RM0.012 (in line with FY 2024). We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. All figures shown in the chart above are for the trailing 12 month (TTM) period Alpha IVF Group Berhad Revenues and Earnings Miss Expectations Revenue missed analyst estimates by 8.9%. Earnings per share (EPS) also missed analyst estimates by 13%. The primary driver behind last 12 months revenue was the Malaysia segment contributing a total revenue of RM157.2m (89% of total revenue). The largest operating expense was General & Administrative costs, amounting to RM33.1m (67% of total expenses). Explore how ALPHA's revenue and expenses shape its earnings. Looking ahead, revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 8.6% growth forecast for the Healthcare industry in Malaysia. Performance of the Malaysian Healthcare industry. The company's shares are up 5.5% from a week ago. Risk Analysis We don't want to rain on the parade too much, but we did also find 2 warning signs for Alpha IVF Group Berhad (1 makes us a bit uncomfortable!) that you need to be mindful of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
